Quantum Genomics raises €3M to initiate Phase IIa study in hypertension
​Quantum Genomics received a regulatory green light to start phase IIa trials with QGC001, their lead drug candidate for resistant hypertension. The company successfully raised €3M through bond financing, allowing the company to initiate Phase IIa studies, before a secondary offering expected in 2015. Resistant hypertension affects 10-15% of hypertensive patients (100-150 million patients worldwide). QGC001 could provide a therapeutic option for millions of patients not responding to current therapies and revolutionize the market of hypertension with its novel mechanism of action. We value Quantum Genomics at €46.8m or €9.72 per share (unchanged from our coverage initiation report).
Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.